Bristol-Myers Squibb Co.: PharmaVitae Profile

This analysis examines the historical and forecast performance for BMS in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Report Highlights

[Fade out the market survey infos]

CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 3
Key findings 3
Prescription pharmaceutical sales performance, 2001–13 3
Financial performance, 2001–13 3
Novo Nordisk: PharmaVitae forecasts at a glance 3
Strategic insight 3
Novo Nordisk – a focus strategy company 3
Big Pharma status from 2011 3
SWOT analysis 3
Strengths 3
Weaknesses 3
Opportunities 3
Threats 3
CHAPTER 3 QUARTERLY NEWS UPDATE 3
Product developments 3
Deals and alliances 3
Product deals 3
Technology deals 3
M&A activity 3
Company announcements 3
Future product milestones 3
CHAPTER 4 COMPANY STRUCTURE 3
Key findings 3
Company overview 3
Company history 3
M&A history 3
Nordisk Gentofte and Novo Industri merger 3
Divestments promote Rx pharma focus 3
Novo Nordisk and Novozymes demerger 3
Demerger of Zymogenetics 3
Acquisition of Biobrγs and Pharmaplan GmbH 3
CHAPTER 5 COMPANY SALES 3
Key findings 3
Prescription pharmaceutical sales and growth rate analysis, 2001–13 3
Product analysis 3
Product analysis, 2001–07 3
Product analysis, 2007–13 3
Therapy area analysis 3
Therapy area analysis, 2001–07 3
Therapy area analysis, 2007–13 3
Therapy area focus, 2001–13 3
Geographic analysis 3
Geographic analysis, 2001–07 3
Geographic analysis, 2007–13 3
Geographic focus, 2001–13 3
Launch/core/expiry analysis 3
Explanation of launch/core/expiry analysis 3
Launch analysis, 2007–13 3
Core analysis, 2007–13 3
Expiry analysis, 2007–13 3
Launch/core/expiry configuration, 2007–13 3
Molecule type analysis 3
Molecule type analysis, 2001–07 3
Molecule type analysis, 2007–13 3
Molecule type focus, 2001–13 3
Externalization analysis 3
Externalization analysis, 2001–07 3
Externalization analysis, 2007–13 3
CHAPTER 6 COMPANY FINANCIALS 3
Key findings 3
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001–07 3
Financial statements, 2001–07 3
Profit and loss account, 2001–07 3
Balance sheet, 2001–07 3
Operating costs and profit analysis 3
Operating costs and profit analysis, 2001–07 3
Operating cost ratio and profit margin analysis, 2001–07 3
Operating cost ratio and profit margin analysis, 2007–13 3
Operating costs and profit analysis, 2007–13 3
Return on capital employed analysis 3
Capital employed analysis, 2001–07 3
Return on capital employed (RoCE) analysis, 2001–07 3
Market capitalization analysis 3
Market capitalization analysis, 2001–07 3
Total shareholder returns analysis, 2001–07 3
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 3
Key findings 3
Overview 3
Diabetes market overview 3
Definition of diabetes 3
Key antidiabetic product classes 3
Key competitors to Novo Nordisk’s antidiabetics portfolio 3
Endocrine, metabolic and genetic disorders 3
NovoRapid/NovoLog 3
NovoMix 3
Levemir 3
Liraglutide 3
Norditropin 3
Hematology 3
NovoSeven 3
CHAPTER 8 APPENDIX 3
R&D pipeline 3
References 3
Abbreviations 3
Exchange rates 3
[Fade out table of contents]

Table 1: Bristol-Myers Squibb – PharmaVitae forecasts at a glance 5
Table 2: Plavix demise set to override 2007–13 growth prospects 5
Table 3: BMS’s therapeutic transformation ($m), 2007–13 5
Table 4: Bristol-Myers Squibb key product developments, Q1-Q2 2008 5
Table 5: Bristol-Myers Squibb product deals and alliances, Q1-Q2 2008 5
Table 6: Bristol-Myers Squibb technology deals and alliances, Q1-Q2 2008 5
Table 7: Bristol-Myers Squibb M&A activity, Q1-Q2 2008 5
Table 8: Bristol-Myers Squibb company announcements, Q1-Q2 2008 5
Table 9: Bristol-Myers Squibb future product milestones, 2008–10 5
Table 10: Bristol-Myers Squibb product portfolio overview ($m), 2001–07 5
Table 11: Bristol-Myers Squibb product portfolio overview ($m), 2007–13 5
Table 12: Bristol-Myers Squibb therapy portfolio overview ($m), 2001–07 5
Table 13: Bristol-Myers Squibb therapy portfolio overview ($m), 2007–13 5
Table 14: Bristol-Myers Squibb portfolio overview by geographic region ($m), 2001–07 5
Table 15: Bristol-Myers Squibb portfolio overview by geographic region ($m), 2007–13 5
Table 16: Bristol-Myers Squibb launch portfolio overview ($m), 2007–13 5
Table 17: Bristol-Myers Squibb core portfolio overview ($m), 2007–13 5
Table 18: Bristol-Myers Squibb expiry portfolio overview ($m), 2007–13 5
Table 19: Bristol-Myers Squibb portfolio overview by molecule type ($m), 2001–07 5
Table 20: Bristol-Myers Squibb product portfolio overview by molecule type ($m), 2007–13 5
Table 21: Bristol-Myers Squibb product portfolio overview by source ($m), 2001–07 5
Table 22: Bristol-Myers Squibb product portfolio overview by source ($m), 2007–13 5
Table 23: Total Bristol-Myers Squibb sales by business unit ($m), 2001–07 5
Table 24: Bristol-Myers Squibb profit and loss account ($m), 2001–07 5
Table 25: Bristol-Myers Squibb balance sheet ($m), 2001–07 5
Table 26: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2001–07 5
Table 27: Bristol-Myers Squibb operating cost ratio analysis (% of total revenues), 2001–07 5
Table 28: Bristol-Myers Squibb operating cost ratio analysis (% of total revenues), 2007–13 5
Table 29: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2007–13 5
Table 30: Bristol-Myers Squibb capital employed ($m), 2001–07 5
Table 31: Bristol-Myers Squibb EBIT return on capital employed ($m), 2001–07 5
Table 32: Bristol-Myers Squibb EBIT pre-tax return/Capital employed driver analysis (%), 2001–07 5
Table 33: Bristol-Myers Squibb market capitalization ($ billion), 2001–07 5
Table 34: Bristol-Myers Squibb total shareholder returns (annual %), 2001–07 5
Table 35: Key products overview 5
Table 36: Erbitux: overview 5
Table 37: Erbitux: sales forecast ($m), 2007–13 5
Table 38: Sprycel: overview 5
Table 39: Sprycel: sales forecast ($m), 2007–13 5
Table 40: Ixempra: overview 5
Table 41: Ixempra: sales forecast ($m), 2007–13 5
Table 42: Sustiva franchise: overview 5
Table 43: Sustiva franchise: sales forecast ($m), 2007–13 5
Table 44: Reyataz: overview 5
Table 45: Reyataz: sales forecast ($m), 2007–13 5
Table 46: Orencia: overview 5
Table 47: Orencia: sales forecast ($m), 2007–13 5
Table 48: Plavix: overview 5
Table 49: Plavix: sales forecast ($m), 2007–13 5
Table 50: Abilify: overview 5
Table 51: Abilify: sales forecast ($m), 2007–13 5
Table 52: Onglyza: overview 5
Table 53: Onglyza: sales forecast ($m), 2007–13 5
Table 54: Bristol-Myers Squibb’s R&D pipeline (Phase I–registration) 5
Table 55: Exchange rates, 2007 5
Figure 1: Bristol-Myers Squibb prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001–13 5
Figure 2: Bristol-Myers Squibb’s financial performance ($m), 2001–13 5
Figure 3: Plavix sales dependency (% of total), 2001–13 5
Figure 4: Bristol-Myers Squibb prescription pharma sales by therapy area (% of total), 2001–13 5
Figure 5: Bristol-Myers Squibb SWOT analysis 5
Figure 6: Current corporate structure 5
Figure 7: Bristol-Myers Squibb prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001–13 5
Figure 8: Bristol-Myers Squibb key sales growth driver & resistors ($m), 2001–07 5
Figure 9: Bristol-Myers Squibb key sales growth drivers & resistors ($m), 2007–13 5
Figure 10: Bristol-Myers Squibb prescription pharmaceutical sales by therapy area ($m), 2001–13 5
Figure 11: Bristol-Myers Squibb prescription pharma sales by therapy area (% of total), 2001–13 5
Figure 12: Bristol-Myers Squibb prescription pharmaceutical sales by geographic region ($m), 2001–13 5
Figure 13: Bristol-Myers Squibb drivers and resistors by geographic region ($m), 2001–07 5
Figure 14: Bristol-Myers Squibb drivers and resistors by geographic region ($m), 2007–13 5
Figure 15: Bristol-Myers Squibb prescription pharmaceutical sales by geographic region (% of total), 2001–13 5
Figure 16: Bristol-Myers Squibb launch/core/expiry configuration ($m), 2007–13 5
Figure 17: Bristol-Myers Squibb prescription pharmaceutical sales by molecule type ($m), 2001–13 5
Figure 18: Bristol-Myers Squibb growth drivers & resistors by molecule type ($m), 2007–13 5
Figure 19: Bristol-Myers Squibb prescription pharmaceutical sales by source ($m), 2001–13 5
Figure 20: Bristol-Myers Squibb growth drivers & resistors by source ($m), 2001–07 5
Figure 21: Bristol-Myers Squibb growth drivers & resistors by source ($m), 2007–13 5
Figure 22: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2001–13 5
Figure 23: Bristol-Myers Squibb operating cost ratio analysis (% of total revenues), 2001–13 5
Figure 24: Bristol-Myers Squibb return on capital employed, EBIT margin and capital turnover, 2001–07 5
Figure 25: Return on capital employed formula 5
Figure 26: Bristol-Myers Squibb market capitalization ($ billion), 2001–07 5
Figure 27: Bristol-Myers Squibb total shareholder returns vs. S&P 500 ($m), 2001–07 5
[Fade out list of tables / figures]